Yasmin M. Syam

33 El Bohouth Street, Dokki
Cairo, C 12622, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery.

Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery.

Journal: European journal of medicinal chemistry

Published: June 27, 2025

CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridine.

CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridine.

Journal: RSC medicinal chemistry

Published: April 20, 2025

Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present).

Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present).

Journal: Bioorganic & medicinal chemistry

Published: February 24, 2025

Design, synthesis, and in silico studies of new benzofuran-pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity.

Design, synthesis, and in silico studies of new benzofuran-pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity.

Journal: RSC advances

Published: January 23, 2025

New Benzofuran-Pyrazole-Based Compounds as Promising Antimicrobial Agents: Design, Synthesis, DNA Gyrase B Inhibition, and In Silico Studies.

New Benzofuran-Pyrazole-Based Compounds as Promising Antimicrobial Agents: Design, Synthesis, DNA Gyrase B Inhibition, and In Silico Studies.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 20, 2024

Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity.

Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity.

Journal: Archiv der Pharmazie

Published: December 10, 2023

Quinazoline-oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies.

Quinazoline-oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies.

Journal: Archiv der Pharmazie

Published: November 21, 2023

Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents.

Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents.

Journal: Bioorganic chemistry

Published: September 04, 2023

Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation.

Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation.

Journal: European journal of medicinal chemistry

Published: July 22, 2023

Anti-Alzheimer activity of new coumarin-based derivatives targeting acetylcholinesterase inhibition.

Anti-Alzheimer activity of new coumarin-based derivatives targeting acetylcholinesterase inhibition.

Journal: RSC advances

Published: April 09, 2023

Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation.

Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation.

Journal: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Published: February 17, 2023

New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.

New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.

Journal: Molecules (Basel, Switzerland)

Published: June 22, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026